NB Development signs life science companies at Boston Landing

October 06, 2017 - Owners Developers & Managers

Brighton, MA NB Development Group, LLC, the development company behind the transformative gateway mixed-use Boston Landing development project along the I-90 Mass Pike, has inked leases with their first two life-science companies.

Roche Diagnostics Operations, Inc. will take occupancy of its space during the first half of 2018. Roche is one of the world’s largest biotech companies, with differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. On this transaction, Roche was represented by the Cushman & Wakefield team of David Klein, Kevin Hanna and Connor Barnes. The NB Development team of Jim Halliday, Bob Graham, Erin Harvey, and Keith Craig represented themselves.

Proteostasis Therapeutics, Inc. will also take occupancy of its space during the first half of 2018. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery of groundbreaking therapies to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Bob Richards of Transwestern represented Proteostasis Therapeutics, while NB Development Group was represented by Transwestern’s Steve Purpura and Perry Beal working with the NB Development Group team of Halliday, Graham, Harvey and Craig.

“We are excited to continue the transformation of Boston Landing with the addition of both Roche Diagnostics and Proteostasis Therapeutics as both are engaged in important and innovative discoveries centered around health & wellness,” said Jim Halliday, managing director of NB Development Group. “The work and values of both these companies align well with enhancing the innovation and health & wellness spirit already entrenched with the presence of New Balance, the Boston Bruins and the Boston Celtics, as well as the investment made by John Hancock in the residential project at Boston Landing. With the growth in life-science activity within the Cambridge-Boston market, at Boston Landing we look forward to continuing our inroads in attracting other innovative life-sciences and other R&D tech minded industries to the Boston Landing campus.”

NB Development Group is a commercial real estate company. The group’s professionals bring Boston-based experience in the fields of development, permitting, construction management, asset management, leasing, and marketing. NBDG is currently managing the development of Boston Landing, a mixed-use project located along the Massa. Pike. Located minutes from Downtown, Boston Landing is a smart growth project consisting of 1.76 million s/f. The development will include diverse property types, including three new laboratory/office buildings, an NHL regulation hockey arena for the Boston Bruins, the newly announced practice facility for the Boston Celtics, a hotel, a world class track & field / multi-sport & event center, a residential apartment building, a commuter rail station on the Framingham/Worcester line and amenity-driven retail. The development is currently home to New Balance Athletics, Inc., Harvard Business School Publishing, Global Atlantic and WGBH amongst other reputable entities.

 

More from the New England Real Estate Journal